Advanced Brain Monitoring Inc., Carlsbad, CA, United States of America.
University of California, San Diego, San Diego, CA, United States of America.
PLoS One. 2021 Feb 5;16(2):e0244180. doi: 10.1371/journal.pone.0244180. eCollection 2021.
In this paper, we explore the utility of resting-state EEG measures as potential biomarkers for the detection and assessment of cognitive decline in mild cognitive impairment (MCI) and Alzheimer's disease (AD). Neurophysiological biomarkers of AD derived from EEG and FDG-PET, once characterized and validated, would expand the set of existing diagnostic molecular biomarkers of AD pathology with associated biomarkers of disease progression and neural dysfunction. Since symptoms of AD often begin to appear later in life, successful identification of EEG-based biomarkers must account for age-related neurophysiological changes that occur even in healthy individuals. To this end, we collected EEG data from individuals with AD (n = 26), MCI (n = 53), and cognitively normal healthy controls stratified by age into three groups: 18-40 (n = 129), 40-60 (n = 62) and 60-90 (= 55) years old. For each participant, we computed power spectral density at each channel and spectral coherence between pairs of channels. Compared to age matched controls, in the AD group, we found increases in both spectral power and coherence at the slower frequencies (Delta, Theta). A smaller but significant increase in power of slow frequencies was observed for the MCI group, localized to temporal areas. These effects on slow frequency spectral power opposed that of normal aging observed by a decrease in the power of slow frequencies in our control groups. The AD group showed a significant decrease in the spectral power and coherence in the Alpha band consistent with the same effect in normal aging. However, the MCI group did not show any significant change in the Alpha band. Overall, Theta to Alpha ratio (TAR) provided the largest and most significant differences between the AD group and controls. However, differences in the MCI group remained small and localized. We proposed a novel method to quantify these small differences between Theta and Alpha bands' power using empirically derived distributions of spectral power across the time domain as opposed to averaging power across time. We defined Power Distribution Distance Measure (PDDM) as a distance measure between probability distribution functions (pdf) of Theta and Alpha power. Compared to average TAR, using PDDF enhanced the statistical significance, the effect size, and the spatial distribution of significant effects in the MCI group. We designed classifiers for differentiating individual MCI and AD participants from age-matched controls. The classification performance measured by the area under ROC curve after cross-validation were AUC = 0.85 and AUC = 0.6, for AD and MCI classifiers, respectively. Posterior probability of AD, TAR, and the proposed PDDM measure were all significantly correlated with MMSE score and neuropsychological tests in the AD group.
在本文中,我们探讨了静息态 EEG 测量作为轻度认知障碍(MCI)和阿尔茨海默病(AD)检测和评估认知能力下降的潜在生物标志物的效用。源自 EEG 和 FDG-PET 的 AD 神经生理学生物标志物一旦得到特征描述和验证,将扩大现有的 AD 病理分子生物标志物集,增加疾病进展和神经功能障碍的生物标志物。由于 AD 的症状通常在生命后期才开始出现,因此成功识别基于 EEG 的生物标志物必须考虑到即使在健康个体中也会发生的与年龄相关的神经生理变化。为此,我们从 AD(n = 26)、MCI(n = 53)患者和按年龄分为三组的认知正常健康对照者(18-40 岁,n = 129;40-60 岁,n = 62;60-90 岁,n = 55)中收集了 EEG 数据。对于每个参与者,我们在每个通道计算了功率谱密度,并在通道对之间计算了谱相干性。与年龄匹配的对照组相比,在 AD 组中,我们发现较慢频率(Delta、Theta)的频谱功率和相干性都增加了。MCI 组也观察到较慢频率的功率略有但显著增加,局限于颞区。这些较慢频率的谱功率效应与我们对照组中正常衰老导致的较慢频率功率下降相反。AD 组在 Alpha 频段的谱功率和相干性显著降低,与正常衰老的相同效应一致。然而,MCI 组在 Alpha 频段没有显示出任何显著变化。总的来说,Theta 与 Alpha 比值(TAR)在 AD 组和对照组之间提供了最大和最显著的差异。然而,MCI 组的差异仍然较小且局限。我们提出了一种新方法,使用从时域中推导出的谱功率分布而不是跨时间平均功率来量化 Theta 和 Alpha 波段功率之间的这些小差异。我们将功率分布距离度量(PDDM)定义为 Theta 和 Alpha 功率概率分布函数(pdf)之间的距离度量。与平均 TAR 相比,使用 PDDF 增强了 MCI 组中统计学意义、效果大小和显著效果的空间分布。我们设计了用于区分个体 MCI 和 AD 参与者与年龄匹配对照组的分类器。经过交叉验证后的 ROC 曲线下面积的分类性能分别为 AD 分类器 AUC = 0.85 和 MCI 分类器 AUC = 0.6。AD 组中 AD、TAR 和提议的 PDDM 测量的后验概率与 MMSE 评分和神经心理学测试均显著相关。